OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.
OST-HER2 is completing a PhIIb clinical trial in 4Q2024 with significantly improved Event Free Survival (EFS), and early Overall Survival (OS).
OST-tADC is a ph-sensitive novel pre-clinical Drug Conjugate that uses proprietary (IP) Silicon to cover and link the multiple payloads until they are delivered to the acidic cancer environment, dissolving the Silicon - delivering and activating the payloads.
Company Details
- Employees
- 10
- Founded
- 2018
- Address
- 101 6th Avenue, 3rd Floor, Jlabs,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ostherapies.com
- Keywords
- Oncology, Osteosarcoma, Pediatric Cancer, Solid Tumors, Ovarian Cancer, Lung Cancer, Breast Cancer.
- HQ
- New York, NY
Os Therapies Questions
Os Therapies's website is http://www.ostherapies.com
Os Therapies's LinkedIn profile is https://www.linkedin.com/company/os-therapies
Os Therapies has
10 employees.
View email and phone details for 10
employees at Os Therapies.
Os Therapies's industry is
Biotechnology Research
Os Therapies's top competitors are
Tenax Therapeutics,
Pharmacosmos,
Sangamo Therapeutics, Inc.,
Agenus,
Madrigal Pharmaceuticals,
Lykos Therapeutics,
Exscientia,
Recursion,
Biomarin Pharmaceutical Inc.,
Curon Biopharmaceutical.
Os Therapies's categories are Biotechnology Research
Os Therapies's founding year is 2018
